PARIS, ONTARIO--(InvestorsHub NewsWire - Dec. 19,
2016) - Emblem Corp. (TSX VENTURE:EMC)
(OTCQB:EMMBF) (the "Company") is pleased to announce that it has
received confirmation from Health Canada that its license under the
ACMPR will be amended to permit the production of cannabis
oils.
"This is an incredibly important milestone for us as a company,"
says Gordon Fox, CEO of Emblem Corp. "With our ability to extract
cannabinoids we can now actively execute the business plan we've
built for our pharmaceutical division."
"Cannabinoids have real therapeutic value, as evidenced by the
products Cesamet, Marinol and Sativex all having been approved as
prescription drugs by Health Canada," says John H. Stewart, CEO of
Emblem Corp's. pharmaceutical division. In addition, there have
been numerous reports published in the scientific literature
pertaining to the medical use of cannabinoids - with evidence of
efficacy in patients with chronic pain, multiple sclerosis, nausea,
neuropathic pain, PTSD and wasting syndrome.
"The active components in cannabis will be extracted, purified
and incorporated into advanced formulations, in order to enhance
their therapeutic utility," adds Stewart.
Emblem Corp. has invested over $1 million CAD to date into its
extraction and purification platform including a supercritical CO2
extractor, purpose built rooms, and analytical equipment.
Emblem has stockpiled a significant amount of both bud and trim
for extraction and is pleased to announce that, in addition to
those rooms in its current facility that will be licensed for
extraction under this amendment, Emblem plans to construct a 2,500
sq. ft. dedicated extraction and formulation development laboratory
on its property in Paris, ON. Additionally, Emblem has hired three
scientists to work exclusively in this division to pursue the
development and manufacture of advanced dosage forms of
cannabinoids.
This license amendment will enable Emblem to better serve
patients by providing a broad range of cannabis products.
About Emblem Cannabis
Emblem is licensed under the Access to Cannabis for Medical
Purposes Regulations (the "ACMPR") to cultivate and sell medical
marijuana. Emblem carries out its principal activities producing
marijuana from its facilities in Paris, Ontario pursuant to the
provisions of the ACMPR and the Controlled Drugs and Substances Act
(Canada) and its regulations.